Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01294319 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men
A Phase 2 study of ACTH and Cortisol Resistance, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT01294319: Completed Phase 2 study of ACTH and Cortisol Resistance, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
NCT01294319 is a Phase 2 study of ACTH and Cortisol Resistance that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 51 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01294319, a Phase 2 study of ACTH and Cortisol Resistance, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
This study proposes to examine multiple aspects of the hypothalamic-pituitary-adrenal axis in younger endurance trained and sedentary men, and in older sedentary men.
Primary Outcome
All subjects will take 0.25mg dexamethasone as an outpatient between 2300 and 2400h and will then report to the clinic by 0800h next day for the final visit. At the final visit, cortisol response to dexamethasone suppression was assessed. The cortisol response was dichotomized (suppression vs. non-suppression, using 1.8 ug/dL as the cutoff point) and compared between the two groups,Sedentary Young Adults and Endurance-trained Young Athletes.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dexamethasone
- DRUG Spironolactone
- DRUG Mifepristone
- DRUG Combined
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2011-01-24 |
| Est. Completion | 2016-08-10 |
| Phase | Phase 2 |
What the finished NCT01294319 record still lists
NCT01294319 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 5 conditions, with ACTH appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT01294319 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01294319 about?
NCT01294319 is a clinical study titled "Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men". This study proposes to examine multiple aspects of the hypothalamic-pituitary-adrenal axis in younger endurance trained and sedentary men, and in older sedentary men.
What is the current status of trial NCT01294319?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2011-01-24. Estimated completion is 2016-08-10.
What conditions does trial NCT01294319 study?
This clinical trial studies the following conditions: ACTH, Cortisol Resistance, Negative Feedback, Mineralcorticoid, Glucocorticoid.
What interventions are being tested in trial NCT01294319?
The interventions under investigation include: Placebo (DRUG), Dexamethasone (DRUG), Spironolactone (DRUG), Mifepristone (DRUG), Combined (DRUG).
Who is sponsoring clinical trial NCT01294319?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01294319 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ACTH
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01294319's enrollment target sits among peer trials
51 1190th of 2000 higher than 806 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI